Effect of elexacaftor/tezacaftor/ivacaftor therapy on serum lipoprotein functions in adults with cystic fibrosis
European Atherosclerosis Journal · 30.04.2026 · 5 (1) · 23
DOI: 10.56095/eaj.v5i1.131 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Atherosclerosis Journal, online erschienen am 30.04.2026. Verfasst von Marcella Palumbo und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Cystic fibrosis is a genetic and multisystemic disease associated with a very poor quality of life and life expectancy. The introduction of the combined treatment with elexacaftor/tezacaftor/ivacaftor (ETI, Kaftrio) has extended the life expectancy of adults with cystic fibrosis (awCF), which could have an impact on the prevalence of certain chronic diseases, such as cardiovascular (CV) diseases. In this regard, in a recent work, it was observed that treatment with Kaftrio has a heterogeneous effect on CV risk factors, ameliorating some of them, such as chronic inflammation, and worsening others. Among the relevant factors determining CV risk, the capacity of HDL to promote cholesterol efflux (HDL-CEC), one of the main functions of this class of lipoproteins, has proven to be a better predictor than plasma HDL concentrations. In addition, the serum capacity to load macrophages with cholesterol (cholesterol loading capacity, CLC) represents an index of serum lipoproteins' pro-atherogenic potential. This work aimed to evaluate the effect of six months of therapy with Kaftrio on serum lipoprotein functions, namely HDL-CEC and serum CLC, in 16 awCF, and in 8 sex and age-matched healthy controls. HDL-CEC through the main pathways was evaluated with a radioisotopic cell-based assay in specific cell models, and serum CLC was assessed fluorimetrically in human monocyte-derived macrophages THP-1. Concerning plasma lipid profile, after treatment with Kaftrio, total cholesterol, LDL-C, and HDL-C significantly increased as compared to baseline (p
Zitieren
APA
Palumbo, M., Greco, C., Gramegna, A., Blasi, F., Ruscica, M., Zimetti, F., & Adorni, M. P. (2026). Effect of elexacaftor/tezacaftor/ivacaftor therapy on serum lipoprotein functions in adults with cystic fibrosis. European Atherosclerosis Journal, 5(1), 23. https://doi.org/10.56095/eaj.v5i1.131
Vancouver
Palumbo M, Greco C, Gramegna A, Blasi F, Ruscica M, Zimetti F, et al. Effect of elexacaftor/tezacaftor/ivacaftor therapy on serum lipoprotein functions in adults with cystic fibrosis. European Atherosclerosis Journal. 2026;5(1):23. doi:10.56095/eaj.v5i1.131
BibTeX
@article{Palumbo2026,
author = {Palumbo, Marcella and Greco, Claudia and Gramegna, Andrea and Blasi, Francesco and Ruscica, Massimiliano and Zimetti, Francesca and Adorni, Maria Pia},
title = {Effect of elexacaftor/tezacaftor/ivacaftor therapy on serum lipoprotein functions in adults with cystic fibrosis},
journal = {European Atherosclerosis Journal},
year = {2026},
volume = {5},
number = {1},
pages = {23},
doi = {10.56095/eaj.v5i1.131}
}
EUVIMED